702 related articles for article (PubMed ID: 32478895)
1. Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal.
Huang SH; O'Sullivan B; Su J; Ringash J; Bratman SV; Kim J; Hosni A; Bayley A; Cho J; Giuliani M; Hope A; Spreafico A; Hansen AR; Siu LL; Gilbert R; Irish JC; Goldstein D; de Almeida J; Tong L; Xu W; Waldron J
Cancer; 2020 Aug; 126(15):3426-3437. PubMed ID: 32478895
[TBL] [Abstract][Full Text] [Related]
2. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
[TBL] [Abstract][Full Text] [Related]
3. The role of concomitant chemoradiotherapy versus radiation alone in T1-3N0 HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma.
Shiao JC; Holt D; Ladbury C; Gao D; Jones B; Karam SD; Amini A
Oral Oncol; 2022 Jul; 130():105907. PubMed ID: 35605559
[TBL] [Abstract][Full Text] [Related]
4. Treatment outcomes and survival following definitive (chemo)radiotherapy in HPV-positive oropharynx cancer: Large-scale comparison of DAHANCA vs PMH cohorts.
Lassen P; Huang SH; Su J; Waldron J; Andersen M; Primdahl H; Johansen J; Kristensen CA; Andersen E; Eriksen JG; Hansen CR; Alsner J; Lilja-Fisher J; Bratman SV; Ringash J; Kim J; Hope A; Spreafico A; de Almeida J; Xu W; O'Sullivan B; Overgaard J
Int J Cancer; 2022 Apr; 150(8):1329-1340. PubMed ID: 34792199
[TBL] [Abstract][Full Text] [Related]
5. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Staar S; Rudat V; Stuetzer H; Dietz A; Volling P; Schroeder M; Flentje M; Eckel HE; Mueller RP
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1161-71. PubMed ID: 11483325
[TBL] [Abstract][Full Text] [Related]
6. Mature results from a Swedish comparison study of conventional versus accelerated radiotherapy in head and neck squamous cell carcinoma - The ARTSCAN trial.
Zackrisson B; Kjellén E; Söderström K; Brun E; Nyman J; Friesland S; Reizenstein J; Sjödin H; Ekberg L; Lödén B; Franzén L; Ask A; Wickart-Johansson G; Lewin F; Björk-Eriksson T; Lundin E; Dalianis T; Wennerberg J; Johansson KA; Nilsson P
Radiother Oncol; 2015 Oct; 117(1):99-105. PubMed ID: 26427805
[TBL] [Abstract][Full Text] [Related]
7. Individualized treatment of head neck squamous cell carcinoma patients aged 70 or older with radiotherapy alone or associated to cisplatin or cetuximab: impact of weekly radiation dose on loco-regional control.
Belgioia L; Bacigalupo A; Missale F; Vecchio S; Chiola I; Callegari S; Verzanini E; Peretti G; Corvò R
Med Oncol; 2019 Mar; 36(5):42. PubMed ID: 30927146
[TBL] [Abstract][Full Text] [Related]
8. Stage I HPV-positive oropharyngeal cancer: Should all patients receive similar treatments?
Yoshida EJ; Luu M; Mallen-St Clair J; Mita AC; Scher KS; Lu DJ; Nguyen AT; Shiao SL; Ho AS; Zumsteg ZS
Cancer; 2020 Jan; 126(1):58-66. PubMed ID: 31536144
[TBL] [Abstract][Full Text] [Related]
9. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis.
O'Sullivan B; Huang SH; Siu LL; Waldron J; Zhao H; Perez-Ordonez B; Weinreb I; Kim J; Ringash J; Bayley A; Dawson LA; Hope A; Cho J; Irish J; Gilbert R; Gullane P; Hui A; Liu FF; Chen E; Xu W
J Clin Oncol; 2013 Feb; 31(5):543-50. PubMed ID: 23295795
[TBL] [Abstract][Full Text] [Related]
10. Radiation Therapy Alone for Human Papillomavirus-Related Squamous Cell Carcinoma of the Oropharynx: A Single-Arm, Phase 2 Study.
Takemoto N; Seo Y; Nakahara S; Yoshioka Y; Teshima T; Fujii T; Isohashi F; Otani K; Yoshii T; Takenaka Y; Suzuki M; Fukusumi T; Hanamoto A; Yasui T; Michiba T; Yamamoto Y; Shimamoto S; Tanaka H; Tatsumi M; Ogawa K; Inohara H
Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):403-411. PubMed ID: 33373656
[TBL] [Abstract][Full Text] [Related]
11. Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer.
de Roest RH; van der Heijden M; Wesseling FWR; de Ruiter EJ; Heymans MW; Terhaard C; Vergeer MR; Buter J; Devriese LA; de Boer JP; Navran A; Hoeben A; Vens C; van den Brekel M; Brakenhoff RH; Leemans CR; Hoebers F
Radiother Oncol; 2022 Oct; 175():112-121. PubMed ID: 35973619
[TBL] [Abstract][Full Text] [Related]
12. Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer.
Beckham TH; Barney C; Healy E; Wolfe AR; Branstetter A; Yaney A; Riaz N; McBride SM; Tsai CJ; Kang J; Yu Y; Chen L; Sherman E; Dunn L; Pfister DG; Tan J; Rupert R; Bonomi M; Zhang Z; Lobaugh SM; Grecula JC; Mitchell DL; Wobb JL; Miller ED; Blakaj DM; Diavolitsis VM; Lee N; Bhatt AD
Int J Cancer; 2020 Jul; 147(1):107-115. PubMed ID: 31609479
[TBL] [Abstract][Full Text] [Related]
13. Radiation therapy dose de-escalation compared to standard dose radiation therapy in definitive treatment of HPV-positive oropharyngeal squamous cell carcinoma.
Gabani P; Lin AJ; Barnes J; Oppelt P; Adkins DR; Rich JT; Zevallos JP; Daly MD; Gay HA; Thorstad WL
Radiother Oncol; 2019 May; 134():81-88. PubMed ID: 31005228
[TBL] [Abstract][Full Text] [Related]
14. Optimization of therapeutic strategy for p16-positive oropharyngeal squamous cell carcinoma: Multi-institutional observational study based on the national Head and Neck Cancer Registry of Japan.
Saito Y; Hayashi R; Iida Y; Mizumachi T; Fujii T; Matsumoto F; Beppu T; Yoshida M; Shinomiya H; Kamiyama R; Kitano M; Yokoshima K; Fujimoto Y; Hama T; Yamashita T; Okami K; Miura K; Fujisawa T; Sano D; Kato H; Minami S; Sugasawa M; Masuda M; Ota I; Iwae S; Kawata R; Monden N; Imai T; Asakage T; Okada M; Yoshikawa T; Tanioka K; Kitayama M; Doi M; Fujii S; Fujii M; Oridate N; Nakamizo M; Yoshimoto S; Homma A; Nibu KI; Yane K
Cancer; 2020 Sep; 126(18):4177-4187. PubMed ID: 32648953
[TBL] [Abstract][Full Text] [Related]
15. Impact of concomitant chemoradiation on survival for patients with T1-2N1 head and neck cancer.
Zumsteg ZS; Kim S; David JM; Yoshida EJ; Tighiouart M; Shiao SL; Scher K; Mita A; Sherman EJ; Lee NY; Ho AS
Cancer; 2017 May; 123(9):1555-1565. PubMed ID: 28001302
[TBL] [Abstract][Full Text] [Related]
16. Classical risk factors, but not HPV status, predict survival after chemoradiotherapy in advanced head and neck cancer patients.
Descamps G; Karaca Y; Lechien JR; Kindt N; Decaestecker C; Remmelink M; Larsimont D; Andry G; Hassid S; Rodriguez A; Khalife M; Journe F; Saussez S
J Cancer Res Clin Oncol; 2016 Oct; 142(10):2185-96. PubMed ID: 27370781
[TBL] [Abstract][Full Text] [Related]
17. A prospective, multicenter DAHANCA study of hyperfractionated, accelerated radiotherapy for head and neck squamous cell carcinoma.
Saksø M; Andersen E; Bentzen J; Andersen M; Johansen J; Primdahl H; Overgaard J; Eriksen JG
Acta Oncol; 2019 Oct; 58(10):1495-1501. PubMed ID: 31519130
[No Abstract] [Full Text] [Related]
18. Systematic Review and Meta-analysis of Conventionally Fractionated Concurrent Chemoradiotherapy versus Altered Fractionation Radiotherapy Alone in the Definitive Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma.
Gupta T; Kannan S; Ghosh-Laskar S; Agarwal JP
Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):50-61. PubMed ID: 26454839
[TBL] [Abstract][Full Text] [Related]
19. Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma.
Spreafico A; Huang SH; Xu W; Granata R; Liu CS; Waldron JN; Chen E; Ringash J; Bayley A; Chan KK; Hope AJ; Cho J; Razak AA; Hansen A; Jang R; Perez-Ordonez B; Weinreb I; Bossi P; Orlandi E; Licitra LF; Song Y; O'Sullivan B; Siu LL; Kim J
Eur J Cancer; 2016 Nov; 67():174-182. PubMed ID: 27669504
[TBL] [Abstract][Full Text] [Related]
20. The role of concomitant chemoradiotherapy in AJCC 7
Lu DJ; Luu M; Nguyen AT; Shiao SL; Scher K; Mita A; Anderson E; Clair JM; Ho AS; Zumsteg ZS
Oral Oncol; 2020 Nov; 110():104882. PubMed ID: 32650257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
